A mission to bring better therapies and innovative peptide-based medicines
to improve quality of life and chronic disease management
Positioned to become a premier Peptide Therapeutics Company, driving innovation and improving lives on a global scale with the development and launch of Syracuse University's GEP-44
Peptide-based drug discovery is an important option to address common therapeutic challenges - GlucaPharm introduces 2 new peptide compound discoveries made by Syracuse University that notably reduce body weight and normalize blood glucose levels without the typical negative side effects experienced by many patients who take currently available GLP-1-based anti-obesity drugs
The Researchers at Syracuse University are Developing Innovative Therapies for Metabolic and Neurological Health:
A Next-Generation Dual-Agonist (GLP-1 & NPY) for Weight Loss and Glucose Control
A triple-agonist peptide targeting GLP-1 and NPY1/NPY2 receptors, offering effective treatment for obesity and type 2 diabetes (T2D) without nausea or vomiting
The mission is to develop an effective, targeted, peptide therapy that provides potent weight loss and glucose control while preserving β-cell mass
Notably, what has been developed to date, delivers these benefits with minimal to no gastrointestinal disturbances or malaise, setting it apart from other GLP-1 agonists
Preclinical studies have demonstrated its equivalent efficacy to Ozempic in achieving weight loss and glucose control, with the added benefit of improved tolerability
GEP44 is part of a series of chimeric peptides designed to target 2 key receptors:
(1) Neuropeptide Y-receptor (Y2-R) to reduce food intake (FI)
(2) GLP1-R to improve glucose regulation
With potential secondary benefits that support cardiovascular health and may aid in reducing opioid addiction/withdrawal symptoms
GlucaPharm has an Exclusive Worldwide Licence
with Syracuse University to Develop GEP-44
Peptide-based Therapies
For Metabolic and Neurological Diseases
Targeting Chronic Disease with Fewer Side Effects
Obesity
Diabetes
Alzheimer’s
Exploring Potential
Opioid Addiction Treatment
and Cardiovascular Health
We Believe in The Power of Expert Collaboration and
Advanced Research, for the Development of Key Therapies that will Improve Quality of Life and Medical Care by Unlocking the Potential of Peptide Drugs
The GEP-44 Journey In Numbers
3
Expert Researchers
2
Breakthrough Peptide Compound Discoveries -GEP44 and KCEM1
$9M
Total Grants Received